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Lung cancerLung cancer is the leading cause of cancer deathworldwide, and has a ﬁve-year survival rate of 18% [1]. MARK2 is
a serine/threonine-protein kinase, and is a key component in the phosphorylation ofmicrotubule-associatedpro-
teins [2,3]. A recent study published by Hubaux et al. found that microtubule afﬁnity-regulating kinase 2
(MARK2) showed highly frequent DNA and RNA level disruption in lung cancer cell lines and independent
non-small cell lung cancer (NSCLC) cohorts [4]. These alterations result in the acquisition of oncogenic properties
in cell lines, such as increased viability and anchorage-independent growth. Furthermore, a microarray-based
transcriptome analysis of three short hairpin RNA (shRNA)-mediated MARK2 knockdown lung adenocarcinoma
cell lines (GEO#: GSE57966) revealed an association between MARK2 gene expression and cell cycle activation
and DNA damage response. Here, we present a detailed description of transcriptome analysis to support the
described role of MARK2 in promoting a malignant phenotype.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ntre, 675 West 10th Avenue,
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1. Experimental design, materials and methods
1.1. Cell lines and study design
In the investigation of the potential oncogenic role ofMARK2 in lung
cancer, three lung adenocarcinoma cell lines (NCI-H1650, NCI-H1993,
NCI-H1693) with high endogenous expression of MARK2were selected
for further gene expressionmanipulation studies. Cells were cultured as
previously described [4]. Lentiviral transductions with either empty
vector PLKO (control) or shRNA targeting MARK2 transcripts were
used to stably modulate MARK2 expression levels (Thermo Fisher,
Canada). RT-qPCR was performed as a validation of transduction
efﬁciency.
1.2. Patient samples
In order to ﬁlter results of gene-set enrichment analysis, human
NSCLC was used. Seventy-seven matched tumor/non-malignant sam-
ples from the British Columbia Cancer Research Centre (BCCRC) cohort
were considered. Tissues were obtained from both male and female
subjects under written, informed consent approved by the University
of British Columbia — BC Cancer Agency Research Ethics Board. Fresh-
frozen tissues were micro-dissected to ensure N80% tumor cell contentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Comparison of raw vs. normalized probe intensity. Box-and-whisker plot of A) raw and B) log2 RMA normalized intensity data. Samples are in the following order: 1) NCI-H1650
pLKO control (Replicate 1), 2)NCI-H1650MARK2Knockdown (Replicate 1), 3)NCI-H1693 pLKOcontrol (Replicate 1), 4) NCI-H1693Mark2 Knockdown (Replicate 1), 5)NCI-H1993 pLKO
control (Replicate 1), 6) NCI-H1993 Mark2 Knockdown (Replicate 1), 7) NCI-H1650 Mark2 Knockdown (Replicate 2), 8) NCI-H1650 pLKO control (Replicate 2), 9) NCI-H1693 pLKO
control (Replicate 2), 10) NCI-H1693 Mark2 Knockdown (Replicate 2), 11) NCI-H1993 pLKO control (Replicate 2), 12) NCI-H1993 Mark2 Knockdown (Replicate 2).
146 E.A. Marshall et al. / Genomics Data 6 (2015) 145–148[5]. A 2-fold change threshold between the tumor/non-malignant pairs
was established to deﬁne differentially expressed genes.
1.3. Microarray experiments
RNA extraction from two biological replicates of each experimental
condition was performed using TRIzol reagent (Life Technologies,
Grand Island, USA). The quality and concentration of total RNA was
assessed using an Agilent Bioanalyzer 2100 (Agilent Technologies,
Foster City, CA). Biotinylated cRNA was prepared from 500 ng of total
RNA and hybridized using the GeneChip Human PrimeView Array
platform (Affymetrix, Santa Clara, CA, USA) for 16 h at 45 °C. Array slides
were washed and stained in the Affymetrix Fluidics Station 400, and
scanned using the Affymetrix GeneChip Scanner 3000. Microarray
data analysis was performed using default analysis settings in
the Affymetrix® Expression Console™ and Partek Genome Suite™
Software.
1.4. Data QC and normalization
Probe cell intensity (.CEL) ﬁles were imported and normalized using
the Robust Multiarray Averaging (RMA) normalization method [6].Fig. 2. Probe intensity distribution: Histogram for intensity distribution on A) raw and B) log2 n
and-whisker plot of each experimental condition are shown at the bottom of each histogram. S
Mark2 Knockdown (Replicate 1), 3) NCI-H1693 pLKOcontrol (Replicate 1), 4)NCI-H1693Mark2
Knockdown (Replicate 1), 7) NCI-H1650 Mark2 Knockdown (Replicate 2), 8) NCI-H1650 pLK
Knockdown (Replicate 2), 11) NCI-H1993 pLKO control (Replicate 2), 12) NCI-H1993 Mark2 KNormalized probe intensities were summarized in order to display
probe-level signal data. Signal intensity before and after log2 RMA signal
transformation is displayed in Fig. 1. Distribution of probe intensity
values was also assessed, conﬁrming that log2-transformed normalized
data is closer to a normal distribution (Fig. 2).
A principal component analysis (PCA) was performed on RMA
normalized expression data. First, the analysis reveled that biological
replicates showed a high degree of correlation for each cell line. The
NCI-H1650 MARK2-KD experiments clustered further apart from PLKO
control in the PCA graph, suggesting that the knockdown of MARK2
had the strongest effect in this cell line. In NCI-H1693 and NCI-H1993
MARK2, knockdown cell lines are closely related to their respective
control counterparts (Fig. 3).1.5. Statistical analysis
All statistical analyses were conducted using GraphPad Prism
version 6.00 for Windows (GraphPad Software, La Jolla California USA,
www.graphpad.com). P values for cell viability and colony formation
for shRNA knockdown of MARK2 were calculated using two-tailed
t-tests. All experiments were performed in triplicate.ormalized data is shown (A bell-shaped curve is overlaid for comparison purposes). Box-
amples are in the following order: 1) NCI-H1650 pLKO control (Replicate 1), 2) NCI-H1650
Knockdown (Replicate 1), 5) NCI-H1993 pLKOcontrol (Replicate 1), 6)NCI-H1993Mark2
O control (Replicate 2), 9) NCI-H1693 pLKO control (Replicate 2), 10) NCI-H1693 Mark2
nockdown (Replicate 2).
Fig. 3. Principal component analysis. A PCA analysis was performed on normalized intensity values on NCI-H1650 (red), NCI-H1693 (blue) and NCI-H1993 (green). The experimental
conditions (knock-down — triangles and pLKO controls, squares) are shown.
147E.A. Marshall et al. / Genomics Data 6 (2015) 145–148Signiﬁcant analysis of microarrays (SAM v4.0) [7] was conducted
using R statistical software (v3.0.1) to determine genes whose expres-
sion is signiﬁcantly changed as a result of MARK2 manipulation. SAMFig. 4. Gene set enrichment analysis: A gene-set enrichment analysis (GSEA) was performed o
genes identiﬁed on NCI-H1993 (green), NCI-H1693 (blue) and NCI-H1650 (red) were chosen
Negatively and positively enriched gene sets are shown in bars to the left and right of the zero
gene sets are shown on the y-axis.analysis includes a multiple-testing correction, whereby p-values are
adjusted to calculate the false-discovery rate (FDR) q-value [8]. Genes
with an estimated FDR q-value b 0.05 were used.n differentially expressed genes between shRNA-MARK2 and controls. Two-fold change
as inputs for A) Transcription factor targets or B) canonical pathways gene sets analysis.
line. A q-value ≤ 0.05 was used a signiﬁcance threshold. Names of signiﬁcantly enriched
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Gene set enrichment analysis (GSEA) algorithmwas used to identify
function signiﬁcantly enriched in shRNA MARK2 cell lines compared to
their controls [9]. The expression proﬁles of the ten highest and lowest
MARK2 expressing tumor-normal pairs from the BCCRC dataset were
assessed to identify genes signiﬁcantly associated with MARK2
expression.
The C3.TFT (Transcription Factor Targets) and C2.CP (Canonical
Pathways) collection from theMolecular Signatures Database (MSigDB)
were selected to preferentially acquire information from canonical
pathway and transcription factor target gene sets in each cell line. In
cell line and tumor analysis, ﬁfty-six gene sets were be signiﬁcantly
enriched. This cohort includes genes associatedwith NF-κB, DNA repair,
E2F, and Myc/Max. Additionally, negative association between NF-κB
and MARK2 expression has been previously observed (Fig. 4).
2. Discussion
The role of MAP/microtubule afﬁnity-regulating kinases have been
extensively studied in multiple cellular processes, however their in-
volvement in cancer development and patient outcome remains to be
deciphered. Results from Hubaux et al. reveal recurrent overexpression
of MARK2 in independent NSCLC cohorts, irrespective of lung cancer
histological subtype. Moreover, the manipulation of MARK2 expression
in lung cancer cell models revealed its involvement in cell viability and
anchorage-independent growth, and provided evidence of its associa-
tion with DNA damage and cisplatin sensitivity [4].
The present study describes the detailed analytical procedures used
to determine the involvement of MARK2 gene expression in the devel-
opment of lung cancer malignant phenotypes including DNA damage
and proliferation. We have presented a thorough characterization of
the nature of the raw data obtained from the transcriptome analysis,
and have illustrated the quality control and normalization procedures.We also describe in detail the data input used for the gene set enrich-
ment analysis that was conducted to elucidate potential biological path-
ways affected by lack of MARK2 expression.
In conclusion, we have provided additional information supporting
the robustness of the data generated as well as the analytical approach
used to analyze the role of MARK2 as a potential lung cancer oncogene.Funding sources
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